Dimerix Limited (SBMJF)

Market Cap	112.56M -41.9%
Revenue (ttm)	4.40M +13.7%
Net Income	-20.62M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	214
Open	0.3500
Previous Close	0.2500
Day's Range	0.3500 - 0.3500
52-Week Range	0.2500 - 0.3500
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Employees: 15
• Stock Exchange: OTCMKTS
• Ticker Symbol: SBMJF

Financial Performance

In fiscal year 2026, Dimerix's revenue was 6.35 million, an increase of 13.73% compared to the previous year's 5.59 million. Losses were -29.81 million, 125.0% more than in 2025.

Financial numbers in AUD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 10, 2026

Data Sources Report a data error